Show simple item record

dc.contributor.authorMansergh, Gordon
dc.contributor.authorKota, Krishna Kiran
dc.contributor.authorStephenson, Rob
dc.contributor.authorHirshfield, Sabina
dc.contributor.authorSullivan, Patrick
dc.date.accessioned2022-10-03T18:49:06Z
dc.date.available2022-10-03T18:49:06Z
dc.identifier.citationMansergh G, Kota KK, Stephenson R, Hirshfield S, Sullivan P. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities. J Int AIDS Soc. 2021 Jan;24(1):e25664. doi: 10.1002/jia2.25664. PMID: 33481359; PMCID: PMC7821953.en_US
dc.identifier.eissn1758-2652
dc.identifier.doi10.1002/jia2.25664
dc.identifier.pmid33481359
dc.identifier.urihttp://hdl.handle.net/20.500.12648/7634
dc.description.abstractBackground: Daily oral pre-exposure prophylaxis (PrEP) is available and recommended for men who have sex with men (MSM) at risk for HIV infection. Other HIV prevention products are being developed, including long-acting injectable (LAI) and event-based oral and topical formulations. Understanding preferences for potential products by MSM can help direct further development of prevention messaging. Methods: We present baseline data from HIV-negative participants enrolled in the US Mobile Messaging for Men (M-cubed) Study. Participants were asked their likelihood of and rank order preference for using daily oral PrEP and various potential prevention products (one- to -three-month injections, 2-1-1 sexual event oral dosing, anal or penile gel, or anal suppository), and their sociodemographic characteristics. Bivariate and multivariable logistics regression assessed demographic associations with likelihood of use and rank order preference. Results: Overall, most MSM reported a likelihood of using LAI (74%), sexual event-based pills (67%) and penile gel (64%). Men who reported recent unprotected (condomless and PrEPless) anal sex most preferred a penile gel formulation (74%), followed closely by LAI and event-based pills (73% each). Current PrEP users (vs. non-users) had greater odds of reporting likelihood to use LAI (AOR = 3.29, 95% CI = 2.12 to 5.11), whereas men reporting recent unprotected anal sex had a greater odds of likelihood to use a penile gel (AOR = 1.79, 95% CI = 1.27 to 2.52) and an anal suppository (AOR = 1.48, 95% CI = 1.08 to 2.02). Hispanic/Latino (vs. White) MSM (AOR = 2.29, 95% CI = 1.40 to 3.73) and, marginally, Black MSM (AOR = 1.54, 95% CI = 1.00 to 2.38) had greater odds of reporting likelihood to use penile gel. Similar patterns were found for rank ordering preference of products, including condoms. Conclusions: Most MSM were interested in using various potential future HIV prevention products, especially LAI. However, two typologies of potential users emerged: men who prefer sexual event-based methods (condoms, event-based pill, sexual gels and suppositories) and men who prefer non-sexual event-based methods (daily pill, LAI). Men who reported recent unprotected anal sex preferred a penile gel product most, followed closely by sexual event-based pills and LAI. Racial/ethnic differences were noted as well. These findings on product preferences can help in formulation development and messaging.en_US
dc.language.isoenen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/10.1002/jia2.25664en_US
dc.rights© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHIVen_US
dc.subjectMSMen_US
dc.subjectPrEPen_US
dc.subjectmen who have sex with menen_US
dc.subjectprevention methodsen_US
dc.subjectprevention productsen_US
dc.subjectprophylaxisen_US
dc.titlePreference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleJournal of the International AIDS Societyen_US
dc.source.volume24
dc.source.issue1
dc.source.beginpagee25664
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countrySwitzerland
dc.description.versionVoRen_US
refterms.dateFOA2022-10-03T18:49:06Z
dc.description.institutionN/Aen_US
dc.description.departmentSTAR Programen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalJournal of the International AIDS Society


Files in this item

Thumbnail
Name:
Journal of the International ...
Size:
143.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Except where otherwise noted, this item's license is described as © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.